Search Result
Results for "
Doxorubicin
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
5
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-116063
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Doxorubicin-SMCC is a agent-linker conjugate for ADC. Doxorubicin-SMCC contains a non-cleavable ADC linker and a DNA topoisomerase II inhibitor Doxorubicin .
|
-
-
- HY-15142
-
Hydroxydaunorubicin hydrochloride
|
Topoisomerase
ADC Cytotoxin
AMPK
Autophagy
Apoptosis
HIV
HBV
Mitophagy
Antibiotic
Bacterial
|
Infection
Cancer
|
Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .
|
-
-
- HY-15142A
-
Hydroxydaunorubicin
|
ADC Cytotoxin
Antibiotic
Bacterial
Topoisomerase
AMPK
HIV
Autophagy
Mitophagy
Apoptosis
HBV
|
Infection
Cancer
|
Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy . Doxorubicin inhibits human DNA topoisomerase I with an IC50 of 0.8 μM .
|
-
-
- HY-15142R
-
|
Topoisomerase
ADC Cytotoxin
AMPK
Autophagy
Apoptosis
HIV
HBV
Mitophagy
Antibiotic
Bacterial
|
Infection
Cancer
|
Doxorubicin (hydrochloride) (Standard) is the analytical standard of Doxorubicin (hydrochloride). This product is intended for research and analytical applications. Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy .
|
-
-
- HY-16261A
-
(E/Z)-AlDoxorubicin; Doxorubicin(6-maleimidocaproyl)hydrazone
|
Topoisomerase
Drug-Linker Conjugates for ADC
|
Cancer
|
MC-DOXHZN ((E/Z)-Aldoxorubicin) is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties .
|
-
-
- HY-16261B
-
(E/Z)-AlDoxorubicin hydrochloride; Doxorubicin(6-maleimidocaproyl)hydrazone hydrochloride
|
Topoisomerase
Drug-Linker Conjugates for ADC
|
Cancer
|
MC-DOXHZN ((E/Z)-Aldoxorubicin) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties .
|
-
-
- HY-G0022
-
13-Dihydroadriamycin hydrochloride
|
Drug Metabolite
|
Cancer
|
Doxorubicinol hydrochloride (13-Dihydroadriamycin hydrochloride) is a secondary alcohol metabolite of Doxorubicin .
|
-
-
- HY-121309S
-
Adriamycin aglycone-d3; Adriamycinone-d3
|
Endogenous Metabolite
|
Cancer
|
Doxorubicinone-d3 is the deuterium labeled Doxorubicinone. Doxorubicinone is a metabolite of an anti-cancer chemotherapy agent Doxorubicin[1]. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively.
|
-
-
- HY-121309
-
Adriamycin aglycone; Adriamycinone
|
Endogenous Metabolite
|
Cancer
|
Doxorubicinone is a metabolite of an anti-cancer chemotherapy agent Doxorubicin . Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively.
|
-
-
- HY-152965
-
-
-
- HY-158329
-
-
-
- HY-136288
-
|
Drug-Linker Conjugates for ADC
|
Cancer
|
Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC) . Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
-
-
- HY-16532
-
AEZS-108; AN-152
|
GnRH Receptor
|
Cancer
|
Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro .
|
-
-
- HY-141158
-
|
ADC Linker
|
Cancer
|
N-(Iodoacetamido)-Doxorubicin is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .
|
-
-
- HY-15794
-
Methoxymorpholinyl Doxorubicin; FCE 23762; PNU 152243
|
G-quadruplex
|
Cancer
|
Nemorubicin (Methoxymorpholinyl doxorubicin) is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
|
-
-
- HY-129410
-
|
Endogenous Metabolite
|
Others
|
ADR-925 is an active chelated iron metabolite with the ability to protect neonatal rat cardiomyocytes from doxorubicin (HY-15142A)-induced damage .
|
-
-
- HY-15794G
-
Methoxymorpholinyl Doxorubicin; FCE 23762; PNU 152243
|
G-quadruplex
|
Cancer
|
Nemorubicin (Methoxymorpholinyl doxorubicin) GMP is a GMP-class Nemorubicin (HY-15794). Nemorubicin is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
|
-
-
- HY-154797
-
|
Others
|
Cancer
|
N,N-Dimethyldoxorubicin is a Doxorubicin (HY-15142A) analogue. N,N-Dimethyldoxorubicin shows cytotoxicity against a panel of tumor cell lines (IC50s < 0.3 μM) .
|
-
-
- HY-W067427
-
|
IKK
|
Cancer
|
BAY32-5915 is a potent IKKα inhibitor with an IC50 value of 60 nM. BAY32-5915 has not affect Doxorubicin (HY-15142A)-induced NF-κB activation .
|
-
-
- HY-P99630
-
MM-302
|
EGFR
|
Cancer
|
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .
|
-
-
- HY-119823
-
|
P-glycoprotein
|
Cancer
|
PGP-4008 is a specific P-glycoprotein (Pgp) inhibitor. PGP-4008 inhibits tumor growth in a murine syngeneic Pgp-mediated multiple agent resistance (MDR) solid tumor model when given in combination with Doxorubicin .
|
-
-
- HY-B0006B
-
(S)-BM 14190
|
Adrenergic Receptor
|
Cardiovascular Disease
|
(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX) .
|
-
-
- HY-B0006C
-
(R)-BM 14190
|
Adrenergic Receptor
|
Cardiovascular Disease
|
(R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX) .
|
-
-
- HY-N10563
-
|
P-glycoprotein
|
Cancer
|
Coleon-U-quinone is a potent P-gp inhibitor. Coleon-U-quinone can inhibit cancer cells viability and sensitize multidrug resistance cancer cells to Doxorubicin (HY-15142A) .
|
-
-
- HY-15434A
-
|
MAP3K
MAP4K
|
Cancer
|
NG25 trihydrochloride is a dual TAK1 and MAP4K2 inhibitor (IC50: 149 nM and 21.7 nM respectively). NG25 sensitizes the breast cancer cells to Doxorubicin (HY-15142A), and enhances apoptosis. NG25 trihydrochloride can be used for research of various cancers .
|
-
-
- HY-100353
-
N-Lauroyl-D-erythro-sphingosine; N-Laurylsphingosine
|
Others
|
Metabolic Disease
Cancer
|
C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease .
|
-
-
- HY-144769
-
|
Topoisomerase
|
Cancer
|
SDOX is the Doxorubicin (DOX) proagent. The loaded DOX proagents (SDOX) which can release the parent agents DOX triggered by excessive GSH in tumor cells, minimize the unexpected side effects on normal tissues without compromising the potency .
|
-
-
- HY-150650
-
|
Others
|
Cancer
|
S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 2.08 μM. S07-2001 enhances the activity of Doxorubicin against cancer cells. S07-2001 has potential as a chemotherapeutic potentiator for cancer agent resistance .
|
-
-
- HY-N3486
-
|
Autophagy
|
Cardiovascular Disease
|
Isodunnianol is a autophagy inducer. Isodunnianol induces autophagy and increases he expression of pAMPK172, pULK1555,decreases teh expression of pULK1757, SQSTM2. Isodunnianol decreases Doxorubicin (HY-15142A)-induced cardiotoxicity .
|
-
-
- HY-145427
-
|
DNA-PK
|
Cancer
|
NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect .
|
-
-
- HY-N144114
-
|
P-glycoprotein
|
Cancer
|
P-gp inhibitor 2 is a potent P-gp inhibitor. P-gp inhibitor 2 shows reverse Doxorubicin resistance (IC50=0.22 µM) in P-gp overexpressing human colorectal carcinoma cells (SW600 Ad300) .
|
-
-
- HY-N10564
-
|
P-glycoprotein
|
Cancer
|
8α,9α-Epoxycoleon-U-quinone (compound 3) is a p-glycoprotein (P-gp) regulator that is selective for cancer cells (SI=2.0). 8α,9α-Epoxycoleon-U-quinone effectively inhibits P-gp activity in NCI-H460/R cells. 8α,9α-Epoxycoleon-U-quinone also reverses the resistance of cancer cells to Doxorubicin (DOX) (HY-15142A) and enhances the anticancer effect of DOX .
|
-
-
- HY-17507
-
BY1023; SKF96022
|
Proton Pump
Autophagy
Apoptosis
Bacterial
|
Inflammation/Immunology
Cancer
|
Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
|
-
-
- HY-17507A
-
BY1023 sodium; SKF96022 sodium
|
Proton Pump
Autophagy
Apoptosis
Bacterial
|
Inflammation/Immunology
Cancer
|
Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
|
-
-
- HY-17507B
-
BY1023 sodium hydrate; SKF96022 sodium hydrate
|
Proton Pump
Autophagy
Apoptosis
Bacterial
|
Inflammation/Immunology
Cancer
|
Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
|
-
-
- HY-Y1832
-
3-Methoxysalicylaldehyde
|
Fungal
|
Infection
Cancer
|
o-Vanillin (2-Vanillin) is a nature product, could be extracted from Vanilla planifolia, Pinus koraiensis fruit. o-Vanillin is a potent antifungal agent. o-Vanillin inhibits the growth of mycelia by disrupting the integrity of cell walls and cell membranes. o-Vanillin inhibits Doxorubicin (HY-15142A)- and 4-hydroperoxycyclophosphamide-induced NF-κB activation .
|
-
-
- HY-13745
-
MEN 10755
|
Topoisomerase
|
Cancer
|
Sabarubicin is a doxorubicin disaccharide analogue with striking antitumor activity. Sabarubicin is more effective than doxorubicin as a topoisomerase II poison and stimulated DNA fragmentation at lower intracellular concentrations.
|
-
-
- HY-17507R
-
|
Proton Pump
Autophagy
Apoptosis
Bacterial
|
Inflammation/Immunology
Cancer
|
Pantoprazole (Standard) is the analytical standard of Pantoprazole. This product is intended for research and analytical applications. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
|
-
-
- HY-153797
-
-
-
- HY-162324
-
|
Survivin
|
Cancer
|
MX106-4C is a survivin inhibitor that selectively kills ABCB1-positive colorectal cancer cells. MX106-4C can exert synergistic anticancer effects with Doxorubicin or resensitize drug-resistant ABCB1 cells to Doxorubicin .
|
-
-
- HY-122182
-
|
Histone Methyltransferase
Apoptosis
|
Cancer
|
OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (DOX; HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX .
|
-
-
- HY-147968
-
|
Others
|
Cancer
|
Anticancer agent 74 is a moderate anticancer agent. Anticancer agent 74 has lower selectivity and cytotoxicity than doxorubicin to normal cell .
|
-
-
- HY-N2591
-
|
Endogenous Metabolite
|
Cancer
|
Isocorydine is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .
|
-
-
- HY-N2591A
-
|
Endogenous Metabolite
|
Cancer
|
Isocorydine hydrochloride is isolated from Dicranostigma leptopodum (Maxim.) Fedde (DLF). Isocorydine hydrochloride combines with Doxorubicin (DOX) has a promising potential to eradicate hepatocellular carcinoma (HCC) .
|
-
-
- HY-126170
-
|
Antibiotic
Bacterial
|
Infection
Cancer
|
Valanimycin is an antibiotic, which inhibits Escherichia coli (BE1121) through interaction with DNA. Valanimycin exhibits cytotoxicity to mouse leukemia L1210, P388/S (doxorubicin (HY-15142A)-sensitive), and P388/ADR (doxorubicin-resistant), with IC50 of 0.79, 2.65, and 1.44 μg/mL, respectively. Valanimycin exhibits antitumor efficacy against ehrlich ascites tumors or L1210 in mice .
|
-
-
- HY-P2004
-
|
MMP
|
Cancer
|
FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .
|
-
-
- HY-157330
-
|
P-glycoprotein
Apoptosis
|
Cancer
|
P-gp inhibitor 16 (compound 14) is a p-glycoprotein inhibitor. P-gp inhibitor 16 significantly increases Doxorubicin-induced apoptosis and shows anticancer effects .
|
-
-
- HY-P2004A
-
|
MMP
|
Cancer
|
FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .
|
-
-
- HY-N3674
-
|
TGF-beta/Smad
|
Inflammation/Immunology
|
Dalbergioidin, a well-known anthocyanin, ameliorates doxorubicin-induced renal fibrosis by suppressing the TGF-β signal pathway. Dalbergioidin exhibits tyrosinase inhibitory activity with an IC50 of 20 mM .
|
-
-
- HY-157484
-
|
P-glycoprotein
|
Cancer
|
P-gp inhibitor 19 (Compound 6i) is a P-gp inhibitor. P-gp inhibitor 19 can inhibit the efflux of rhodamine 123 (HY-D0816) in P-gp-overexpressing leukemia cells K562/Dox and also restore the sensitivity of DOX-resistant cells .
|
-
- HY-117071
-
Ro 115-1240
|
Adrenergic Receptor
Apoptosis
|
Cardiovascular Disease
Endocrinology
|
Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function .
|
-
- HY-N1514
-
|
P-glycoprotein
|
Cancer
|
Ganoderenic acid B is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderenic acid B exhibits potent reversal effect on ABCB1-mediated multidrug resistance of HepG2/ADM cells to Doxorubicin .
|
-
- HY-110067
-
-
- HY-146391
-
|
P-glycoprotein
|
Cancer
|
P-gp inhibitor 4 (Compound 8b) is a selective P-glycoprotein modulator with an EC50 of 94 nM. P-gp inhibitor 4 increases agent transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells .
|
-
- HY-14942A
-
RTA 744; WP 744; WP 769 hydrochloride
|
Apoptosis
|
Cancer
|
Berubicin hydrochloride (RTA 744) is a Doxorubicin (HY-15142A) analogue. Berubicin hydrochloride triggers apoptosis and cell killing in NB cells by activating proapoptotic mediators. Berubicin hydrochloride has proapoptotic and anti-leukemia activities. Berubicin hydrochloride can be used for cancer research .
|
-
- HY-129301
-
|
BCRP
|
Cancer
|
CCTA-1523 is a potent, selective, reversible and orally active ABCG2 inhibitor. CCTA-1523 shows cytotoxicity. CCTA-1523 shows anticancer activity .
|
-
- HY-110075
-
|
Others
|
Cardiovascular Disease
|
Dexrazoxane monohydrochloride is the hydrochloride of Dexrazoxane (HY-B0581). Dexrazoxane prevents or reduces cardiac injury .
|
-
- HY-161013
-
|
Others
|
Others
|
Antiproliferative agent-44 (compound 3) is a potent inhibitor of proliferation, with the IC50 values ranging from 2.02 to 1.61 μM .
|
-
- HY-B0006BS
-
-
- HY-16261
-
INNO-206; DOXO-EMCH
|
Topoisomerase
ADC Cytotoxin
|
Cancer
|
Aldoxorubicin (INNO-206) is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
|
-
- HY-B1041
-
Pimagedine hydrochloride; GER-11; Aminoguanidinium chloride
|
NO Synthase
Apoptosis
|
Endocrinology
|
Aminoguanidine hydrochloride (Pimagedine hydrochloride) is an inhibitor of diamine oxidase and nitric oxide synthase. Aminoguanidine hydrochloride has a dose-dependent inhibitory effect on apoptosis induced by Doxorubicin (HY-15142). Aminoguanidine hydrochloride has antioxidant properties. Aminoguanidine hydrochloride can be used in diabetic nephropathy research .
|
-
- HY-100489
-
tert-Butylhydroquinone
|
Keap1-Nrf2
ERK
Autophagy
Apoptosis
Ferroptosis
|
Cancer
|
TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2 . TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma .
|
-
- HY-D0226
-
1,4-Dihydroxyanthraquinone
|
DNA/RNA Synthesis
Fungal
|
Infection
Cancer
|
Quinizarin (1,4-Dihydroxyanthraquinone), a part of the anticancer agents such as Doxorubicin, Daunorubicin, and Adriamycin, interacts with DNA by intercalating mode (Kd=86.1 μM). Quinizarin is used as a fungicide and pesticide chemical and has shown the ability to inhibit tumor cell growth .
|
-
- HY-16261C
-
INNO-206 hydrochloride; DOXO-EMCH hydrochloride
|
Topoisomerase
ADC Cytotoxin
|
Cancer
|
Aldoxorubicin (INNO-206) hydrochloride is an albumin-binding proagent of Doxorubicin (DNA topoisomerase II inhibitor), which is released from albumin under acidic conditions. Aldoxorubicin hydrochloride (INNO-206) has potent antitumor activities in various cancer cell lines and in murine tumor models.
|
-
- HY-B1041A
-
Pimagedine; GER-11(free base) ; Aminoguanidinium
|
NO Synthase
Apoptosis
|
Endocrinology
|
Aminoguanidine (Pimagedine hydrochloride) is an inhibitor of diamine oxidase and nitric oxide synthase. Aminoguanidine has a dose-dependent inhibitory effect on apoptosis induced by Doxorubicin (HY-15142). Aminoguanidine has antioxidant properties. Aminoguanidine can be used in diabetic nephropathy research .
|
-
- HY-13624A
-
4'-EpiDoxorubicin hydrochloride
|
DNA/RNA Synthesis
Topoisomerase
Apoptosis
Antibiotic
|
Cancer
|
Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
|
-
- HY-13624
-
4'-EpiDoxorubicin
|
DNA/RNA Synthesis
Topoisomerase
Apoptosis
Antibiotic
|
Cancer
|
Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
|
-
- HY-120504
-
|
Bacterial
|
Infection
Cancer
|
N-Acetyltyramine is a quorum-sensing inhibitor (QSI) compound produced by V. alginolyticus M3-10. N-Acetyltyramine is capable of inhibiting the QS of C. violaceum ATCC 12472. N-acetyltyramine reverses resistance in Doxorubicin-resistant leukemia P388 cells .
|
-
- HY-N10642
-
|
Others
|
Others
|
Pedaliin 6''-acetate (compound 10) is a natural product that can be isolated from Dracocephalum tanguticum. Pedaliin 6''-acetate shows antioxidative activity and cytoprotective effect on doxorubicin (DOX)-induced toxicity in H9c2 cardiomyocytes with an EC50 value of 19.1 μM .
|
-
- HY-160774
-
|
Drug-Linker Conjugates for ADC
Topoisomerase
|
Cancer
|
Val-Cit-PABC-DOX (compound 10109), an epsilon-poly-L-lysine-based drug conjugate, is an agent-linker conjugate for ADC by using a DNA topoisomerase I and topoisomerase II inhibitor, Doxorubicin (HY-15142), linked via the linker, Val-Cit-PABC .
|
-
- HY-B0006CS
-
(R)-BM 14190-d4
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Cardiovascular Disease
|
(R)-Carvedilol-d4 is deuterium labeled (R)-Carvedilol. (R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].
|
-
- HY-162128
-
|
Histone Acetyltransferase
|
Cancer
|
Antitumor agent-130 (Compound 7b) is a p300 histone acetyltransferases (HAT) inhibitor with an IC50 of 1.51 μM. Antitumor agent-130 combinates with doxorubicin (HY-15142A) can significantly inhibit tumor growth and invasion in vitro and in vivo .
|
-
- HY-16700
-
|
ADC Cytotoxin
Topoisomerase
|
Cancer
|
PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
|
-
- HY-N6635
-
|
Fungal
|
Infection
Cancer
|
trans-Nerolidol is a sesquiterpene alcohol. It can be isolated from f aerial parts of Warionia saharae ex Benth. trans-Nerolidol improves the anti-proliferative effect of Doxorubicin (HY-15142A) against intestinal cancer cells in vitro. trans-Nerolidol also has anti-fungal activity .
|
-
- HY-147971
-
|
Parasite
Topoisomerase
|
Infection
Cancer
|
Anticancer agent 75 is a potent anticancer agent. Anticancer agent 75 shows cytotoxicity and selectivity in cancer cell lines. Anticancer agent 75 shows cytotoxicity to normal human kidney cell lines is at least 35 times lower than that of the Doxorubicin standard. Anticancer agent 75 shows good activity of antiplasmodial .
|
-
- HY-B0655
-
SQ26991
|
Angiotensin-converting Enzyme (ACE)
Reactive Oxygen Species
|
Cardiovascular Disease
|
Zofenopril Calcium (SQ26991) is an orally active angiotensin-converting enzyme (ACE) inhibitor with antioxidant activity and cardioprotective effects. Zofenopril Calcium reduces ROS production and GSH consumption and helps inhibit foam cell formation, thus slowing the progression of atherosclerosis. Zofenopril Calcium prevents cardiac damage caused by chronic Doxorubicin (HY-15142A).
|
-
- HY-12458
-
|
DNA/RNA Synthesis
|
Infection
Cancer
|
Pyrindamycin A is an antibiotic that inhibits DNA synthesis. Pyrindamycin A shows antitumor activities against murine leukemia, exhibits stronger cytotoxic activities towards murine and human tumor cell lines and especially towards doxorubicin-resistant cells, inhibits P388 and P388/ADR cells with the same IC50 of 3.9 μg/ml .
|
-
- HY-N10595
-
|
Others
|
Others
|
Ladanetin-6-O-β-(6′′-O-acetyl)glucoside is a flavonoid isolated from the whole plants of Dracocephalum tanguticum, with antioxidant ability. Flavonoids from Dracocephalum tanguticum show cardioprotective effects against Doxorubicin (HY-15142A)-induced toxicity in H9c2 cells .
|
-
- HY-146565
-
|
DNA-PK
|
Cancer
|
DNA-PK-IN-8 is a highly potent, selective and orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of 0.8 nM. DNA-PK-IN-8 exhibits synergistic antiproliferative activity against a series of cancer cell lines and significantly suppresses HL-60 tumor growth, when using in combination with Doxorubicin .
|
-
- HY-155035
-
|
Others
|
Cancer
|
S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells .
|
-
- HY-100489R
-
tert-Butylhydroquinone (Standard)
|
Keap1-Nrf2
ERK
Autophagy
Apoptosis
Ferroptosis
|
Cancer
|
TBHQ (Standard) is the analytical standard of TBHQ. This product is intended for research and analytical applications. TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2 . TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma .
|
-
- HY-152188
-
-
- HY-155463
-
|
NOD-like Receptor (NLR)
Interleukin Related
|
Inflammation/Immunology
|
NLRP3-IN-25 (compound 32) is an orally available NLRP3 inhibitor with anti-inflammatory activity. NLRP3-IN-25 attenuates renal injury in doxorubicin-induced glomerulonephritis in mice. NLRP3-IN-25 inhibits IL-1β secretion in THP-1 cells with an IC50 of 21 nM .
|
-
- HY-16700G
-
|
ADC Cytotoxin
Topoisomerase
|
Cancer
|
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
|
-
- HY-120295
-
|
Endothelin Receptor
Apoptosis
|
Cardiovascular Disease
Endocrinology
|
A-192621 is a potent, nonpeptide, orally active and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. The selectivity of A-192621 is 636-fold higher than ETA (IC50 of 4280 nM and Ki of 5600 nM). A-192621 promotes apoptosis in PASMCs. A-192621 alos causes elevation of arterial blood pressure and an elevation in the plasma ET-1 level .
|
-
- HY-150565
-
|
P-glycoprotein
|
Cancer
|
P-gp inhibitor 5 is a potent P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 5 has antiproliferative activity against certain cancer cell lines. P-gp inhibitor 5 is effective in reversing the multidrug resistance (MDR) phenotype in ABCB1/Flp-In TM-293 and KBvin cells by restoring their sensitivity to Vincristine (HY-N0488A) and Paclitaxel (HY-B0015) .
|
-
- HY-N10562
-
|
P-glycoprotein
|
Cancer
|
Mutabilol (compound 1) is a potent p-glycoprotein (P-gp) regulator. Mutabilol is a nature product could be isolated from Plectranthus mutabilis leaves. Mutabilol increases the P-gp expression in NCI-H460/R cells .
|
-
- HY-19541A
-
|
Epigenetic Reader Domain
|
Cancer
|
I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (Kds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin .
|
-
- HY-144825
-
|
Apoptosis
Reactive Oxygen Species
|
Cancer
|
Chol-CTPP is a ligand with dual targeting effect on blood-brain barrier (BBB) and glioma cells. Lip-CTPP can be gained by Chol-CTPP and another mitochondria targeting ligand (Chol-TPP). Lip-CTPP is a promising potential carrier to exert the anti-glioma effect of doxorubicin (DOX) and lonidamine (LND) collaboratively. Lip-CTPP elevates the inhibition rate of tumor cell proliferation, migration and invasion, promote apoptosis and necrosis, and interfere with mitochondrial function .
|
-
- HY-17507S
-
BY1023-d6; SKF96022-d6
|
Isotope-Labeled Compounds
Proton Pump
Autophagy
Apoptosis
|
Inflammation/Immunology
Cancer
|
Pantoprazole-d6 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
|
-
- HY-17507S1
-
BY1023-d3; SKF96022-d3
|
Isotope-Labeled Compounds
Proton Pump
Autophagy
Apoptosis
|
Inflammation/Immunology
Cancer
|
Pantoprazole-d3 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
|
-
- HY-155152
-
|
P-glycoprotein
BCRP
|
Cancer
|
P-gp/BCRP-IN-2 (compound 15) is an oxadiazole derivative and a dual inhibitor of the ABC transporter P-glycoprotein (IC50: 1.6 nM) and BCRP (IC50: 600 nM). P-gp/BCRP-IN-2 also enhances the anti-proliferative effects of Doxorubicin (HY-15142A) in drug-resistant human adenocarcinoma colon cancer cell lines HT29/DX and MDCK-MDR1 cells .
|
-
- HY-129379
-
|
ADC Cytotoxin
|
Cancer
|
DC0-NH2 is an effector moiety for ADC and a simplified analog of DC1 with better stability. DC0-NH2 is about 1000-fold more cytotoxic than commonly used anticancer agents (ex. Doxorubicin). DC0-NH2 can bind to the minor groove of DNA, followed by alkylation of adenine residues by its propabenzindole (CBI) component .
|
-
- HY-16160
-
|
Autophagy
ICMT
|
Cancer
|
Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .
|
-
- HY-17507AR
-
BY1023 sodium (Standard); SKF96022 sodium (Standard)
|
Proton Pump
Autophagy
Apoptosis
Bacterial
|
Inflammation/Immunology
Cancer
|
Pantoprazole (sodium) (Standard) is the analytical standard of Pantoprazole (sodium). This product is intended for research and analytical applications. Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
|
-
- HY-N1346
-
Robinin
2 Publications Verification
|
Toll-like Receptor (TLR)
Apoptosis
|
Inflammation/Immunology
|
Robinin is a flavonoid that can be extracted from the leaves of purple cowpea, inhibiting TGF-β, TLR4/NF-κB and TLR2-PI3k-AKT signaling pathways. Robinin exerts anti-inflammatory and anti-tumor effects. The combination of Robinin and Methotrexate (HY-14519) reduces inflammation in experimental arthritis, Robinin can decrease the Doxorubicin (HY-15142A) induced cardiac toxicity effect .
|
-
- HY-13755
-
|
HDAC
Keap1-Nrf2
Apoptosis
Bcl-2 Family
Caspase
Reactive Oxygen Species
|
Inflammation/Immunology
Cancer
|
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .
|
-
- HY-13755A
-
L-Sulforaphane
|
Keap1-Nrf2
Bcl-2 Family
Caspase
Reactive Oxygen Species
NF-κB
|
Inflammation/Immunology
Cancer
|
(R)-Sulforaphane (L-Sulforaphane) is a orally active, potent inducer of the Keap1/Nrf2/ARE pathway, exhibiting antioxidant and anticancer activities. (R)-Sulforaphane primarily functions by upregulating phase II detoxifying enzymes in cells, aiding in the removal of carcinogens and combating oxidative stress. (R)-Sulforaphane is capable of modulating gene expression, influencing various signaling pathways, including Nrf2, NF-κB, and AP-1. (R)-Sulforaphane can be used in studies of tumor biology, antioxidant defense mechanisms, as well as inflammation and immune responses .
|
-
- HY-10071
-
|
Organoid
ROCK
Apoptosis
|
Cancer
|
Y-27632 is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .
|
-
- HY-157169
-
AMU302
|
Pim
mTOR
Akt
PI3K
|
Cancer
|
IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab (HY-P9907) resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629) .
|
-
- HY-10071A
-
|
Organoid
ROCK
Apoptosis
|
Cancer
|
Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .
|
-
- HY-13915
-
|
Apoptosis
|
Cancer
|
NSC348884 is a nucleophosmin (NPM) inhibitor, it disrupts oligomer formation and induces apoptosis, inhibits cell proliferation with IC50s of 1.7-4.0 μM in distinct cancer cell lines. NSC348884 can be used for the research of cancer .
|
-
- HY-N1441
-
Afzelin
3 Publications Verification
Kaempferol-3-O-rhamnoside
|
Mitochondrial Metabolism
PTEN
Autophagy
Bacterial
|
Infection
Cardiovascular Disease
Neurological Disease
Inflammation/Immunology
|
Afzelin (Kaempferol-3-O-rhamnoside)It is a flavonol glycoside that has anti-inflammatory, anti-oxidative stress response, anti-apoptotic, and anti-cardiac cytotoxic effects. AfzelinIt can reduce mitochondrial damage, enhance mitochondrial biosynthesis, and reduce mitochondria-related proteins. Parkinand PTENinduced putative kinase 1 (putative kinase 1)s level. AfzelinCan be improved D-galactosamine(GalN)/LPSSurvival rate of mice treated with doxorubicin prophylaxis (HY-15142A)Induced cardiotoxicity and scopolamine (HY-N0296)-induced neurological injury. AfzelinAlso inhibits asthma and allergies caused by ovalbumin .
|
-
- HY-162101
-
|
Topoisomerase
|
Cancer
|
Topoisomerase inhibitor 3 (compound 9) is a potent inhibitor of Topoisomerase. Topoisomerase inhibitor 3 has anti-tumor activity .
|
-
- HY-110122
-
|
mGluR
|
Neurological Disease
|
AZ 12216052 is a mGluR8 positive allosteric modulator, and helps mGluR8 modulate signaling inputing to retinal ganglion cells. AZ 12216052 exhibits antianxiety effect .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-D0226
-
1,4-Dihydroxyanthraquinone
|
Fluorescent Dyes/Probes
|
Quinizarin (1,4-Dihydroxyanthraquinone), a part of the anticancer agents such as Doxorubicin, Daunorubicin, and Adriamycin, interacts with DNA by intercalating mode (Kd=86.1 μM). Quinizarin is used as a fungicide and pesticide chemical and has shown the ability to inhibit tumor cell growth .
|
-
- HY-15794G
-
Methoxymorpholinyl Doxorubicin (GMP); FCE 23762 (GMP); PNU 152243 (GMP)
|
Fluorescent Dye
|
Nemorubicin (Methoxymorpholinyl doxorubicin) GMP is a GMP-class Nemorubicin (HY-15794). Nemorubicin is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
|
-
- HY-16700G
-
|
Fluorescent Dye
|
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
|
Cat. No. |
Product Name |
Type |
-
- HY-15794G
-
Methoxymorpholinyl Doxorubicin (GMP); FCE 23762 (GMP); PNU 152243 (GMP)
|
Biochemical Assay Reagents
|
Nemorubicin (Methoxymorpholinyl doxorubicin) GMP is a GMP-class Nemorubicin (HY-15794). Nemorubicin is a Doxorubicin derivative with potent antitumor activity. Nemorubicin is highly cytotoxic to a variety of tumor cell lines presenting a multidrug-resistant phenotype. Nemorubicin not only intercalate into the duplex DNA, but also result in significant ligands for G-quadruplex DNA segments, stabilizing their structure. Nemorubicin requirs an intact nucleotide excision repair (NER) system to exert its activity .
|
-
- HY-16700G
-
|
Biochemical Assay Reagents
|
PNU-159682 GMP is a GMP grade PNU-159682 (HY-16700). PNU-159682, a metabolite of the anthracycline Nemorubicin, is a highly potent DNA topoisomerase II inhibitor with excellent cytotoxicity. PNU-159682 acts as a more potent and tolerated ADC cytotoxin than Doxorubicin for ADC synthesis. PNU-159682 can be used in EDV-nanocell technology to overcome agent resistance.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3669
-
-
- HY-16532
-
AEZS-108; AN-152
|
GnRH Receptor
|
Cancer
|
Zoptarelin doxorubicin (AEZS-108; AN-152) is a hybrid anticancer agent, containing Zoptarelin and Doxorubicin. Zoptarelin doxorubicin has been used to research targeting tumors expressing LHRH receptors. Zoptarelin doxorubicin abolishes tumor progression and induces remarkable apoptosis in vitro .
|
-
- HY-P2004
-
|
MMP
|
Cancer
|
FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .
|
-
- HY-P2004A
-
|
MMP
|
Cancer
|
FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .
|
-
- HY-P10453
-
|
Peptides
|
Others
|
Myr5A peptide is an acylated peptide composed of apolipoprotein A1 (ApoA1) analog peptide 5A peptide coupled to the saturated fatty acid myristate. Myr5A peptide self-assembled into lipid nanostructures can be used to encapsulate anthracycline Doxorubicin (HY-15142A) and Valrubicin (HY-13772) for compound release studies in vitro .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99630
-
MM-302
|
EGFR
|
Cancer
|
Gancotamab (MM-302) is a HER2-targeted antibody-liposomal Doxorubicin conjugate with antitumor activity. Gancotamab encapsulates Doxorubicin to facilitate its delivery to HER2-overexpressing tumor cells .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-121309S
-
|
Doxorubicinone-d3 is the deuterium labeled Doxorubicinone. Doxorubicinone is a metabolite of an anti-cancer chemotherapy agent Doxorubicin[1]. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively.
|
-
-
- HY-B0006BS
-
|
(S)-Carvedilol-d4 is deuterium labeled (S)-Carvedilol. (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].
|
-
-
- HY-B0006CS
-
|
(R)-Carvedilol-d4 is deuterium labeled (R)-Carvedilol. (R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].
|
-
-
- HY-17507S
-
|
Pantoprazole-d6 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
|
-
-
- HY-17507S1
-
|
Pantoprazole-d3 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-136288
-
|
|
Azide
|
Azide-PEG4-VC-PAB-Doxorubicin is a agent-linker conjugate composed of a cytotoxic anthracycline antibiotic Doxorubicin and a linker Azide-PEG4-VC-PAB to make antibody agent conjugate (ADC) . Azide-PEG4-VC-PAB-Doxorubicin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: